According to a press release from Theseus Pharmaceuticals, the company is no longer enrolling patients in its clinical trial for THE-630 in patients with gastrointestinal stromal tumors (GIST). The company also says it will be terminating the development of THE-630 for this use case.
Theseus came to this decision after reporting several negative events in its clinical trial. That includes one patient experiencing grade 3 hand-foot skin reaction. This saw it expand the cohort, which then included another patient that experienced grade 2 hand-foot skin reaction.
Theseus Pharmaceuticals says that these reactions show that THE-630 at 27 mg “exceeds the maximum tolerated dose.” Unfortunately, the company also says that the treatment doesn’t have a differentiated profile at doses below that.
Tim Clackson, Ph.D., President and CEO of Theseus Pharmaceuticals, said the following about the news:
“We are disappointed that we will not be able to achieve the target exposure for pan-variant inhibition with THE-630, as we continue to believe a therapy with potent activity against all major classes of activating and resistance mutations in KIT has the potential to confer significant clinical benefit, given the unmet need in GIST.”
What This Means for THRX Stock
News of the negative clinical trial results is a major blow to THRX stock today. This has the stock falling 67.8% as of Friday morning with some 862,000 shares on the move. For comparison, the company’s daily average trading volume is about 219,000 shares.
Investors looking for even more of the most recent stock market news will want to keep reading!
InvestorPlace is home to all of the hottest stock market news that traders will want to read about on Friday! A few examples include what has shares of Ainos (NASDAQ:AIMD) and Frequency Therapeutics (NASDAQ:FREQ) stock up today, as well as the biggest pre-market stock movers this morning. All of that news is ready to go below!
More Friday Stock Market News
- Why Is Ainos (AIMD) Stock Up 82% Today?
- Why Is Frequency Therapeutics (FREQ) Stock Up 44% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.